RUA Life Sciences (LON:RUA) Rating Reiterated by Shore Capital

Shore Capital reissued their suspended rating on shares of RUA Life Sciences (LON:RUAGet Rating) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports.

LON:RUA opened at GBX 40 ($0.49) on Thursday. RUA Life Sciences has a fifty-two week low of GBX 38.85 ($0.48) and a fifty-two week high of GBX 168 ($2.07). The stock has a market capitalization of £8.87 million and a P/E ratio of -3.85. The company has a debt-to-equity ratio of 5.20, a quick ratio of 5.93 and a current ratio of 6.12. The company’s 50-day simple moving average is GBX 46.98 and its 200-day simple moving average is GBX 72.48.

RUA Life Sciences Company Profile (Get Rating)

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components.

See Also

Receive News & Ratings for RUA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RUA Life Sciences and related companies with's FREE daily email newsletter.